BUZZ-Viking Therapeutics rises after it starts late-stage study of obesity drug
Reuters
Jun 25
BUZZ-Viking <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after it starts late-stage study of obesity drug
** Shares of drug developer Viking Therapeutics VKTX.O rise 1.1% to $27.25 premarket
** VKTX says it has started a late-stage study of its experimental GLP-1 obesity drug candidate, VK2735, in both oral and injectable formulations
** The late-stage study will test the drug in adults with obesity and in overweight or obese adults with type 2 diabetes over 78 weeks, company says
** As of last close, VKTX stock down 33% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.